Holen Sie sich die Stockscreener-App
176.93
1.97%
3.41
Handel nachbörslich:
177.16
0.23
+0.13%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$173.52
Offen:
$172.71
24-Stunden-Volumen:
2.46M
Relative Volume:
2.30
Marktkapitalisierung:
$25.77B
Einnahmen:
$9.67B
Nettoeinkommen (Verlust:
$1.16B
KGV:
9.6315
EPS:
18.37
Netto-Cashflow:
$1.47B
1W Leistung:
-3.56%
1M Leistung:
-4.71%
6M Leistung:
-18.66%
1J Leistung:
-29.09%
1-Tages-Spanne:
$170.72
$177.25
1-Wochen-Bereich:
$170.71
$185.00
52-Wochen-Spanne:
$170.71
$268.30
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Biogen's SWOT analysis: stock outlook amid pipeline challenges, market shifts - Investing.com
Biogen Inc. (NASDAQ:BIIB) Holdings Decreased by US Bancorp DE - MarketBeat
Vanguard Group Inc's Strategic Acquisition of Biogen Inc Shares - GuruFocus.com
Biosimilars Market 2024-2031 Market Analysis: Growth Trends, Demand, and Forecast Overview | Biogen Idec Inc - EIN News
Biogen (NASDAQ:BIIB) Price Target Cut to $210.00 by Analysts at JPMorgan Chase & Co. - MarketBeat
Biogen stock touches 52-week low at $173.01 amid market challenges - Investing.com Canada
Biogen (BIIB) Loses -6.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Wedbush Issues Negative Estimate for Biogen Earnings - MarketBeat
Biogen Analysts Slash Their Forecasts After Q3 Results - MSN
Executive reshuffles: BIIB, USB and WES - MSN
New York State Teachers Retirement System Lowers Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Sage Prioritizes Zurzuvae For PPD, Ends MDD Effort, Drops Zulresso - Scrip
Biogen Inc. stock underperforms Friday when compared to competitors - MarketWatch
What is William Blair's Forecast for Biogen Q4 Earnings? - MarketBeat
Biogen, Eisai seek FDA nod for injectable Leqembi (BIIB:NASDAQ) - Seeking Alpha
Rx Rundown: AbbVie, Biogen, GSK and more - MM+M Online
Biogen Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
Eisai, Biogen eye 2025 approval for Leqembi autoinjector - pharmaphorum
Eisai Completes Rolling Submission to US FDA for LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status - StockTitan
Eisai Completes Rolling Submission to US FDA for LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status - Biogen | Investor Relations
Roche weighs whether speedy approval path is open for latest Alzheimer’s drug - BioPharma Dive
Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter (BIIB) - Seeking Alpha
Biogen Inc (BIIB) Trading Down 3.15% on Oct 31 - GuruFocus.com
Biogen (NASDAQ:BIIB) Reaches New 1-Year LowShould You Sell? - MarketBeat
Biogen's (BIIB) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Biogen stock slips as Morgan Stanley downgrades (BIIB:NASDAQ) - Seeking Alpha
Biogen, Neomorph pact worth $1.45B for molecular glue degraders - BioWorld Online
Biogen Inc. (NASDAQ:BIIB) Q3 2024 Earnings Call Transcript - Insider Monkey
Recurrent Energy Announces Successful Operation of 134 MW Solar Project - The Manila Times
Biogen shares target lifted by Piper Sandler as diversification strategy unfolds - Investing.com
Biogen Inc (BIIB) Q3 2024 Earnings Call Highlights: Navigating R - GuruFocus.com
Diversify Advisory Services LLC Acquires Shares of 4,719 Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Morgan Stanley downgrades Biogen stock as Leqembi launch disappoints - Investing.com
Biogen's Q3 Profit Beats Expectations On Lower Multiple Sclerosis Revenues But New Products Offset Losses, Raises Profit Outlook - MSN
Biogen Inc (BIIB) Q3 2024 Earnings Call Highlights: Navigating Revenue Declines and Strategic ... - Yahoo Finance
Biogen Inc. Raises 2024 Financial Outlook Amid Product Launch Success - TipRanks
Biogen/Eisai announce latest findings for Leqembi in Alzheimer’s disease - TipRanks
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference - Biogen | Investor Relations
Eisai Presents Data on Benefits of Long-Term Administration - GlobeNewswire
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference – Company AnnouncementFT.com - Financial Times
Biogen, Sage Therapeutics Drop Plans to Develop Partnered Drug in Major Depressive Disorder - MedCity News
Earnings call: Biogen reports progress and strategic pipeline expansion - Investing.com
Goldman Sachs maintains Buy on Biogen with $290 target - Investing.com
Biogen Announces CFO Transition and Regulation FD Update - TipRanks
Biogen Sinks. Why A Surprise Boost From Its Alzheimer's Drug Wasn't Enough. - Investor's Business Daily
Leqembi global sales hit $67M, but US adoption remains a challenge - FirstWord Pharma
Biogen Beats on Q3 Earnings & Sales, Raises '24 EPS View - Yahoo Finance
Biogen and Neomorph enter molecular glue degrader deal - Pharmaceutical Technology
Biogen (BIIB) Q3 2024 Earnings Call Transcript - The Motley Fool
Biogen Exceeds EPS Estimate, Revenue Declines - The Motley Fool
Hints of impatience grow with Biogen as it tries to find a bridge to growth - Endpoints News
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):